Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2671 to 2685 of 9071 results

  1. Wasp venom immunotherapy for treating wasp venom allergy

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  3. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  4. Fenfluramine for treating seizures associated with Dravet syndrome in people under 2 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Bee venom immunotherapy for generalised or systemic IgE-mediated allergic reactions to bee venom

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Venglustat for treating Fabry disease

    Awaiting development Reference number: GID-TA12452 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib for treating newly diagnosed unmethylated glioblastoma

    Awaiting development Reference number: GID-TA12449 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTG10887 Expected publication date:  13 October 2026

    HealthTech guidance
    In development

  13. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development